Pulmonary vein cryoballoon ablation for atrial fibrillation demonstrated a 97.9% acute success rate and a 1.4% major complication rate in a large real-world cohort.
Observational (n=903)
Does pulmonary vein isolation with cryoballoon ablation provide high acute success and safety in a real-world cohort of patients with atrial fibrillation?
Cryoballoon ablation for atrial fibrillation demonstrates high acute procedural success (97.9%) and a low major complication rate (1.4%) in a large real-world cohort, with procedural times decreasing as experience grows.
BACKGROUND: Catheter ablation (CA) is recommended for patients with drug refractory symptomatic atrial fibrillation (AF). "One Shot" catheters have been introduced to simplify CA and cryoballoon ablation (CBA) is spreading rapidly. Few real-world data are available on standard clinical practice, mainly from single-center experience. We aimed to evaluate clinical settings, demographics, and acute procedural outcomes in a large cohort of patients treated with CBA. METHODS: A total of 903 patients (73% male, mean age 59 ± 11) underwent pulmonary vein CBA. Correlations between the patient's inclusion time and clinical characteristics, procedure duration, acute success rate, and intraprocedural complications were evaluated. RESULTS: Seventy-seven percent of patients were affected by paroxysmal AF and 23% by persistent AF. Overall, acute success rate was 97.9% and periprocedural complications were observed in 35 (3.9%) patients, 13 (1.4%) of which were classified as major complications. With respect to the patient's inclusion time analysis, an increase in treatment of persistent AF was observed, a significant decrease in CBA times (procedure, ablation, and fluoroscopy: 136.0 ± 46.5 minutes, 28.8 ± 19.6 minutes, and 34.3 ± 15.4 minutes, respectively) was observed, with comparable acute success rate and intraprocedural complications over time. The rate of major complications was extremely low (1.4%); no death, atrioesophageal fistula, stroke, or other major periinterventional or late complications occurred. CONCLUSION: This series represents the largest experience of CBA in the treatment of AF that also describes the adoption curve of this relatively recent technology. CBA showed an excellent safety profile when performed in a large real-world clinical setting, with satisfactory acute success rate and, on average, short procedural times. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov (NCT01007474).
Padeletti et al. (Mon,) conducted a observational in Atrial fibrillation (n=903). Pulmonary vein cryoballoon ablation was evaluated on Acute success rate. Pulmonary vein cryoballoon ablation for atrial fibrillation demonstrated a 97.9% acute success rate and a 1.4% major complication rate in a large real-world cohort.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: